挪威1998-2019年百日咳流行病学及儿童百日咳加强疫苗接种的直接和间接效果
研究纳入挪威1998-2019年报告的74675例百日咳病例,计算各年龄组年发病率,用泊松回归估计2006-2012年和2013-2019年的发病率比。结果显示加强剂对目标年龄组提供直接保护,成人可能获间接保护,婴儿发病率无显著变化;2013-2019年1-15岁儿童发病率上升,需密切监测并进一步评估接种程序。
要点
- 2006-2012年8-15岁发病率从433降至199/10万,IRR 0.89(95%CI 0.88-0.90)。
- 2013-2019年16-19岁发病率从171降至77/10万,IRR 0.84(95%CI 0.82-0.86)。
- 婴儿发病率两个时期均无显著变化,2013-2019年1-15岁发病率上升。
核心结论
- 百日咳加强剂在目标年龄组提供了直接保护,成人可能获得间接保护,但婴儿发病率未变;近期1-15岁发病率上升需密切监测并进一步评估接种程序。
研究设计与样本
- 纳入挪威1998-2019年传染病监测系统报告的所有百日咳病例,共74675例,按年龄组计算年发病率(每10万居民),使用泊松回归估计2006-2012年和2013-2019年各年龄组年均发病率比(IRR)。
主要发现
- 2006-2012年8-15岁发病率从433降至199/10万,IRR 0.89(95%CI 0.88-0.90)。
- 2013-2019年16-19岁发病率从171降至77/10万,IRR 0.84(95%CI 0.82-0.86)。
- 2006-2012年<1岁婴儿IRR 0.99(95%CI 0.95-1.04),2013-2019年IRR 0.96(95%CI 0.91-1.02),均无显著变化。
- 2006-2012年20-39岁和40岁以上成人IRR分别为0.94(95%CI 0.93-0.95)和0.92(95%CI 0.91-0.92);2013-2019年分别为0.97(95%CI 0.96-0.99)和0.97(95%CI 0.96-0.99)。
- 2013-2019年1-7岁发病率从63升至86/10万,IRR 1.05(95%CI 1.03-1.07);8-15岁从88升至122/10万,IRR 1.08(95%CI 1.06-1.10)。
临床怎么用
- 作者认为近期1-15岁发病率上升需密切监测并进一步评估接种程序。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The acellular pertussis vaccine has been used in the Norwegian national immunisation program since 1998. Following an increase in pertussis incidence in all age groups, booster doses were introduced for 7-8-year-olds in 2006, and for 15-16-year-olds in 2013. We assessed the effects of the booster doses on pertussis incidence in different age groups to inform potential changes in vaccination policy. METHODS: We included all pertussis cases notified to the Norwegian Surveillance System for Communicable Diseases in 1998-2019. We calculated annual incidence rates (IR, per 100,000 inhabitants) by age group. We estimated average annual changes in IRs (incidence rate ratios, IRR) for each age group for 2006-2012 and 2013-2019 using Poisson regression. RESULTS: In 1998-2019, 74,675 cases of pertussis were notified. Coinciding with booster introduction, between 2006 and 2012 the IR decreased among 8-15-year-olds (from 433 to 199/100,000, IRR 0.89 [95% confidence interval 0.88-0.90]). A similar decrease was seen between 2013 and 2019 among 16-19-year-olds (from 171 to 77/100,000, IRR 0.84 [0.82-0.86]). There was no significant change in IRs among children < 1 year of age between 2006 and 2012 (IRR 0.99 [0.95-1.04]) or 2013-2019 (IRR 0.96 [0.91-1.02]). The IR decreased in both periods among adults aged 20-39 and 40+ (IRR 0.94 [0.93-0.95] and 0.92 [0.91-0.92] in 2006-2012; IRR 0.97 [0.96-0.99] and 0.97 [0.96-0.99] in 2013-2019, respectively). Despite steady, high vaccination coverage, in 2013-2019, there was an increase in the IR among children aged 1-7 (63 to 86/100,000, IRR 1.05 [1.03-1.07]) and 8-15 years (88 to 122/100,000, IRR 1.08 [1.06-1.10]). CONCLUSIONS: Pertussis booster doses have offered direct protection in the targeted age groups. Our findings suggest indirect protection in adults, while the incidence in infants hasn't changed. The recent increase in IRs among 1-15-year-olds warrants close monitoring and further evaluation of the vaccination schedule.
引用
- Seppälä E, Bråthen Kristoffersen A, Bøås H, et al. Pertussis epidemiology including direct and indirect effects of the childhood pertussis booster vaccinations, Norway, 1998-2019. Vaccine. 2022. PMID: 35469697. doi:10.1016/j.vaccine.2022.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。